AU2003284399A1 - Plk inhibitors - Google Patents
Plk inhibitorsInfo
- Publication number
- AU2003284399A1 AU2003284399A1 AU2003284399A AU2003284399A AU2003284399A1 AU 2003284399 A1 AU2003284399 A1 AU 2003284399A1 AU 2003284399 A AU2003284399 A AU 2003284399A AU 2003284399 A AU2003284399 A AU 2003284399A AU 2003284399 A1 AU2003284399 A1 AU 2003284399A1
- Authority
- AU
- Australia
- Prior art keywords
- plk inhibitors
- plk
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002-331141 | 2002-11-14 | ||
| JP2002331141 | 2002-11-14 | ||
| PCT/JP2003/014518 WO2004043936A1 (en) | 2002-11-14 | 2003-11-14 | Plk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003284399A1 true AU2003284399A1 (en) | 2004-06-03 |
Family
ID=32310616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003284399A Abandoned AU2003284399A1 (en) | 2002-11-14 | 2003-11-14 | Plk inhibitors |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPWO2004043936A1 (en) |
| AU (1) | AU2003284399A1 (en) |
| WO (1) | WO2004043936A1 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ547794A (en) | 2003-12-18 | 2009-11-27 | Janssen Pharmaceutica Nv | Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents |
| US7521457B2 (en) * | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| EP1790650B1 (en) | 2004-08-31 | 2014-03-26 | Msd Kk | NEW SUBSTITUTED IMIDAZOLE DERIVATIVES |
| NI200700147A (en) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | QUINAZOLINE DERIVATIVES KINE INHIBITORS TARGETING MULTIP |
| CA2590939C (en) * | 2004-12-17 | 2011-10-18 | Amgen Inc. | Aminopyrimidine compounds and methods of use |
| DE102005005395A1 (en) * | 2005-02-03 | 2006-08-10 | Schering Aktiengesellschaft | New thiazolidinone compounds are polo-like kinase inhibitors, useful for treating e.g. cancer, autoimmune diseases, cardiovascular diseases, infectious diseases, nephrological diseases and viral diseases |
| WO2007032445A1 (en) * | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | Protein kinase inhibitors |
| US20090124645A1 (en) | 2005-10-14 | 2009-05-14 | Neurosearch A/S | Novel Pyrimidine-2,4-Diamine Derivatives and their Use as Modulators of Small-Conductance Calcium-Activated Potassium Channels |
| US7504513B2 (en) | 2006-02-27 | 2009-03-17 | Hoffman-La Roche Inc. | Thiazolyl-benzimidazoles |
| CA2654583C (en) | 2006-07-13 | 2015-11-24 | Janssen Pharmaceutica N.V. | Mtki quinazoline derivatives |
| EP2815750A1 (en) * | 2006-12-21 | 2014-12-24 | Vertex Pharmaceuticals Incorporated | 5-cyano-4-(pyrrolo [2,3b] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors |
| US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
| JP5536647B2 (en) | 2007-07-27 | 2014-07-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Pyrrolopyrimidine |
| EP2100894A1 (en) | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
| WO2010024430A1 (en) | 2008-09-01 | 2010-03-04 | アステラス製薬株式会社 | 2,4-diaminopyrimidine compound |
| CA2745596A1 (en) | 2008-12-18 | 2010-10-28 | F. Hoffmann-La Roche Ag | Thiazolyl-benzimidazoles |
| HRP20140265T1 (en) * | 2009-02-06 | 2014-04-25 | Nippon Shinyaku Co., Ltd. | Aminopyrazine derivative and drug |
| JPWO2012020786A1 (en) * | 2010-08-11 | 2013-10-28 | 日本新薬株式会社 | Pharmaceutical composition |
| WO2012020787A1 (en) * | 2010-08-11 | 2012-02-16 | 日本新薬株式会社 | Malignant lymphoma therapeutic agent |
| ES2953347T3 (en) | 2014-09-19 | 2023-11-10 | Forma Therapeutics Inc | Pyridin-2(1H)-one quinolinone derivatives as inhibitors of mutant isocitrate dehydrogenase |
| JP6648116B2 (en) * | 2014-09-19 | 2020-02-14 | フォーマ セラピューティクス,インコーポレイテッド | Quinolinone pyrimidine compositions as mutant isocitrate dehydrogenase inhibitors |
| US9624216B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| WO2018203691A1 (en) * | 2017-05-02 | 2018-11-08 | 한국화학연구원 | Pyrimidine derivative compound, optical isomer thereof, or pharmaceutically acceptable salt thereof, and composition for preventing or treating tyro 3 related disease comprising same as active ingredient |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| TW202508595A (en) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2383546A1 (en) * | 1999-06-30 | 2001-01-04 | William H. Parsons | Src kinase inhibitor compounds |
| CA2401016A1 (en) * | 2000-02-25 | 2001-08-30 | University Of California | Scytonemin and methods of using thereof |
-
2003
- 2003-11-14 AU AU2003284399A patent/AU2003284399A1/en not_active Abandoned
- 2003-11-14 WO PCT/JP2003/014518 patent/WO2004043936A1/en not_active Ceased
- 2003-11-14 JP JP2004551234A patent/JPWO2004043936A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2004043936A1 (en) | 2006-03-09 |
| WO2004043936A1 (en) | 2004-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003284399A1 (en) | Plk inhibitors | |
| AU2003202263A1 (en) | Roh-kinase inhibitors | |
| AU2003249442A1 (en) | Kinase inhibitors | |
| AU2003222055A1 (en) | Kinase inhibitors | |
| EG25482A (en) | Inhibitors | |
| AU2003271566A1 (en) | Pyrrolopyrazines as kinase inhibitors | |
| AU2003300832A1 (en) | NF-KappaB INHIBITORS | |
| AU2003249683A1 (en) | Nf-:b inhibitors | |
| AU2003302588A1 (en) | Phosphodiesterase 10a inhibitors | |
| AU2003295427A1 (en) | Flaviviris fusion inhibitors | |
| AU2003244080A1 (en) | Phosphodiesterase inhibitor | |
| AU2003252593A1 (en) | Sulfotransferase inhibitors | |
| AU2003224941A1 (en) | NF-KappaB INHIBITORS | |
| AUPS251402A0 (en) | Kinase inhibitors | |
| AU2003232362A1 (en) | 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors | |
| AU2002318053A1 (en) | Suplier | |
| AU2002950185A0 (en) | Enzyme inhibitors | |
| AU2002341221A1 (en) | Honey-brandy | |
| AU2003212130A1 (en) | Can | |
| HK1084131A (en) | Neuropilin-1 inhibitors | |
| HK1072553A (en) | Kinase inhibitors | |
| AU2003239203A1 (en) | Furano- and thienopyrimidines as neurokinase inhibitors | |
| AU2002100280A4 (en) | Proshoe | |
| AU2002100508A4 (en) | Photocard | |
| AU2002100739A4 (en) | Neuramax |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |